Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Wendling

Showing results (31-40 of 496) with videos related to

Pageof 50
Sort By:
Joint Bone Spine|February 2, 2025
Destructive arthropathy of the shoulder secondary to syringomyeliaDaniel Wendling
Immunotherapy|April 5, 2019
New targeted therapies in spondyloarthritis: what are the limits?Daniel Wendling
Current Rheumatology Reports|June 28, 2012
Uveitis in seronegative arthritisDaniel Wendling
Expert Opinion on Pharmacotherapy|January 9, 2003
Recent progress in ankylosing spondylitis treatmentEric Toussirot, Daniel Wendling
Joint Bone Spine|November 17, 2023
Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis?Philippe Goupille, Daniel Wendling
Joint Bone Spine|July 6, 2011
Mechanic's handsDaniel Wendling, Clément Prati
Joint Bone Spine|March 28, 2006
Metastatic malignant melanoma in a patient taking interleukin-1 receptor antagonistDaniel Wendling, François Aubin
Drugs|September 17, 2014
Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs"Daniel Wendling, Clément Prati
Joint Bone Spine|July 24, 2007
TNFalpha antagonist therapy in patients with joint disease and chronic viral infectionDaniel Wendling, Georges Herbein
Immunotherapy|February 25, 2017
Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritisDaniel Wendling, Clément Prati
Pageof 50

Showing results (31-40 of 496) with videos related to

Sort By:
Pageof 50
Joint Bone Spine|February 2, 2025
Destructive arthropathy of the shoulder secondary to syringomyeliaDaniel Wendling
Immunotherapy|April 5, 2019
New targeted therapies in spondyloarthritis: what are the limits?Daniel Wendling
Current Rheumatology Reports|June 28, 2012
Uveitis in seronegative arthritisDaniel Wendling
Expert Opinion on Pharmacotherapy|January 9, 2003
Recent progress in ankylosing spondylitis treatmentEric Toussirot, Daniel Wendling
Joint Bone Spine|November 17, 2023
Initial C-reactive protein level: Discriminating between anti-TNF and anti-IL-17 agents as the first biologic treatment for axial spondyloarthritis?Philippe Goupille, Daniel Wendling
Joint Bone Spine|July 6, 2011
Mechanic's handsDaniel Wendling, Clément Prati
Joint Bone Spine|March 28, 2006
Metastatic malignant melanoma in a patient taking interleukin-1 receptor antagonistDaniel Wendling, François Aubin
Drugs|September 17, 2014
Comment on "treat-to-target in spondyloarthritis: implications for clinical trial designs"Daniel Wendling, Clément Prati
Joint Bone Spine|July 24, 2007
TNFalpha antagonist therapy in patients with joint disease and chronic viral infectionDaniel Wendling, Georges Herbein
Immunotherapy|February 25, 2017
Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritisDaniel Wendling, Clément Prati
Pageof 50